Sinopharm Group Future Growth
Future criteria checks 1/6
Sinopharm Group is forecast to grow earnings and revenue by 5% and 7% per annum respectively. EPS is expected to grow by 5.1% per annum. Return on equity is forecast to be 8.1% in 3 years.
Key information
5.0%
Earnings growth rate
5.1%
EPS growth rate
| Healthcare earnings growth | 16.2% |
| Revenue growth rate | 7.0% |
| Future return on equity | 8.1% |
| Analyst coverage | Good |
| Last updated | 27 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 731,617 | 10,822 | 10,800 | 16,917 | 14 |
| 12/31/2025 | 674,971 | 9,941 | 11,468 | 13,705 | 16 |
| 12/31/2024 | 613,404 | 8,844 | 5,191 | 16,072 | 10 |
| 6/30/2024 | 597,186 | 9,070 | 13,996 | 16,273 | N/A |
| 3/31/2024 | 598,318 | 8,884 | 8,035 | 10,385 | N/A |
| 12/31/2023 | 596,570 | 9,054 | 14,889 | 17,173 | N/A |
| 9/30/2023 | 314,876 | 5,645 | 54,462 | 55,882 | N/A |
| 6/30/2023 | 314,816 | 5,816 | 53,596 | 55,091 | N/A |
| 3/31/2023 | 570,067 | 8,688 | 14,469 | 16,763 | N/A |
| 12/31/2022 | 552,148 | 8,526 | 18,648 | 20,964 | N/A |
| 9/30/2022 | 546,147 | 7,914 | 6,159 | 8,507 | N/A |
| 6/30/2022 | 533,403 | 7,870 | 492 | 2,783 | N/A |
| 3/31/2022 | 528,383 | 7,970 | 5,378 | 7,658 | N/A |
| 12/31/2021 | 521,051 | 7,759 | 7,081 | 9,308 | N/A |
| 9/30/2021 | 510,091 | 7,930 | 4,511 | 6,795 | N/A |
| 6/30/2021 | 501,770 | 7,874 | 8,743 | 10,983 | N/A |
| 3/31/2021 | 482,281 | 7,591 | 5,833 | 7,950 | N/A |
| 12/31/2020 | 456,415 | 7,187 | 9,099 | 11,155 | N/A |
| 9/30/2020 | 440,194 | 6,615 | 5,998 | 8,075 | N/A |
| 6/30/2020 | 427,372 | 6,174 | 2,304 | 4,522 | N/A |
| 3/31/2020 | 424,494 | 5,918 | 6,510 | 8,813 | N/A |
| 12/31/2019 | 425,273 | 6,251 | 16,417 | 18,777 | N/A |
| 9/30/2019 | 406,394 | 6,311 | -5 | 2,113 | N/A |
| 6/30/2019 | 382,717 | 6,012 | -224 | 1,744 | N/A |
| 3/31/2019 | 360,760 | 6,087 | -5,010 | -3,011 | N/A |
| 12/31/2018 | 344,526 | 5,834 | 392 | 3,654 | N/A |
| 9/30/2018 | 336,113 | 5,523 | -9,906 | -6,868 | N/A |
| 6/30/2018 | 334,060 | 5,606 | -170 | 2,882 | N/A |
| 3/31/2018 | 318,414 | 5,083 | N/A | -6,249 | N/A |
| 12/31/2017 | 308,354 | 5,572 | N/A | 3,209 | N/A |
| 9/30/2017 | 288,855 | 5,217 | N/A | -19 | N/A |
| 6/30/2017 | 269,356 | 4,861 | N/A | -3,247 | N/A |
| 3/31/2017 | 264,691 | 4,996 | N/A | N/A | N/A |
| 12/31/2016 | 258,388 | 4,635 | N/A | 9,258 | N/A |
| 9/30/2016 | 251,401 | 4,515 | N/A | 11,117 | N/A |
| 6/30/2016 | 244,414 | 4,394 | N/A | 12,975 | N/A |
| 3/31/2016 | 234,499 | 3,885 | N/A | N/A | N/A |
| 12/31/2015 | 228,673 | 3,772 | N/A | 13,412 | N/A |
| 9/30/2015 | 222,513 | 3,548 | N/A | 9,472 | N/A |
| 6/30/2015 | 216,353 | 3,323 | N/A | 5,533 | N/A |
| 3/31/2015 | 207,865 | 3,037 | N/A | N/A | N/A |
| 12/31/2014 | 200,131 | 2,875 | N/A | 5,561 | N/A |
| 9/30/2014 | 190,883 | 2,719 | N/A | 5,747 | N/A |
| 6/30/2014 | 181,635 | 2,564 | N/A | 5,933 | N/A |
| 3/31/2014 | 174,251 | 2,407 | N/A | 5,437 | N/A |
| 12/31/2013 | 166,866 | 2,250 | N/A | 4,941 | N/A |
| 9/30/2013 | 158,436 | 2,211 | N/A | 4,547 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1099's forecast earnings growth (5% per year) is above the savings rate (2.3%).
Earnings vs Market: 1099's earnings (5% per year) are forecast to grow slower than the Hong Kong market (10.9% per year).
High Growth Earnings: 1099's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1099's revenue (7% per year) is forecast to grow slower than the Hong Kong market (7.4% per year).
High Growth Revenue: 1099's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1099's Return on Equity is forecast to be low in 3 years time (8.1%).